Arbejdsmarkedets Tillaegspension Buys Shares of 191,826 Abbott Laboratories $ABT

Key Points

• Arbejdsmarkedets Tillaegspension opened a new position in Abbott Laboratories, buying 191,826 shares valued at about $24.0 million in the fourth quarter.
• Abbott’s latest earnings beat expectations, with $1.15 EPS on $11.16 billion in revenue, and the company also issued FY 2026 guidance of 5.38–5.58 EPS.
• Wall Street remains moderately bullish overall: analysts have an average “Moderate Buy” rating and a consensus price target of $119.43, even after some recent target cuts and rating downgrades.

Arbejdsmarkedets Tillaegspension bought a new stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 191,826 shares of the healthcare product maker's stock, valued at approximately $24,034,000.

Several other institutional investors and hedge funds have also recently modified their holdings of ABT. American National Bank of Texas grew its holdings in shares of Abbott Laboratories by 2.4% during the fourth quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker's stock worth $427,000 after purchasing an additional 79 shares in the last quarter. Nia Impact Advisors LLC increased its position in shares of Abbott Laboratories by 2.2% in the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker's stock worth $504,000 after purchasing an additional 79 shares during the last quarter. Connable Office Inc. increased its position in shares of Abbott Laboratories by 0.5% in the third quarter. Connable Office Inc. now owns 15,042 shares of the healthcare product maker's stock worth $2,015,000 after purchasing an additional 81 shares during the last quarter. Park Place Capital Corp increased its position in shares of Abbott Laboratories by 11.0% in the fourth quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker's stock worth $102,000 after purchasing an additional 81 shares during the last quarter. Finally, Lantern Wealth Advisors LLC increased its position in shares of Abbott Laboratories by 1.7% in the third quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker's stock worth $674,000 after purchasing an additional 84 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Wall Street Analyst Weigh In

ABT has been the topic of several research analyst reports. Weiss Ratings cut shares of Abbott Laboratories from a "hold (c)" rating to a "hold (c-)" rating in a research report on Friday, April 24th. Daiwa Securities Group cut Abbott Laboratories from an "outperform" rating to a "neutral" rating and set a $92.00 price target on the stock. in a research note on Wednesday, April 22nd. Piper Sandler cut their price objective on Abbott Laboratories from $135.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, April 17th. Citigroup cut their price objective on Abbott Laboratories from $136.00 to $108.00 and set a "buy" rating on the stock in a research report on Friday, April 17th. Finally, Royal Bank Of Canada cut their price objective on Abbott Laboratories from $135.00 to $130.00 and set an "outperform" rating on the stock in a research report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories has an average rating of "Moderate Buy" and an average target price of $119.43.

Abbott Laboratories Trading Up 1.2%

NYSE ABT opened at $84.80 on Friday. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $139.06. The stock has a market cap of $147.70 billion, a P/E ratio of 23.75, a P/E/G ratio of 1.40 and a beta of 0.65. The stock's fifty day moving average price is $99.59 and its 200-day moving average price is $113.55. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion for the quarter, compared to analysts' expectations of $10.99 billion. During the same period in the prior year, the firm posted $1.09 earnings per share. The company's quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories's dividend payout ratio is currently 70.59%.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the stock in a transaction dated Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Mary K. Moreland sold 613 shares of the company's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by corporate insiders.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: TipRanks highlighted Abbott as one of three “Strong Buy” Dividend Aristocrat stocks, which can support the stock’s appeal for income-focused investors despite a high payout ratio. 3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26
• Neutral Sentiment: Jim Cramer called Abbott one of the “greatest American companies” while comparing the selloff to the 1999 market backdrop, a comment that may help sentiment but does not change fundamentals. Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment
• Neutral Sentiment: Recent insider-trading coverage noted buying activity around Abbott, which can be viewed as a modest confidence signal but is not necessarily a major catalyst on its own. Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell (ABT)
• Negative Sentiment: Investor concerns remain centered on Abbott’s post-earnings weakness, with commentary pointing to Exact Sciences dilution, legal risks, and softer Diagnostics trends as reasons the shares have been pressured. Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold?

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.